Related Experiment Video

Updated: Aug 12, 2026

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation
09:04

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation

Published on: September 7, 2010

Inhibition of influenza A virus replication by rifampicin and selenocystamine

M Hamzehei, N Ledinko

    Journal of Medical Virology
    |January 1, 1980
    PubMed

    Insights

    Selenocystamine and rifampicin effectively inhibited influenza virus replication in eggs. Both antiviral agents demonstrated significant reduction in hemagglutinating and infective virus yields when administered early post-infection.

    Area of Science:

    • Virology
    • Antimicrobial Research

    Background:

    • Influenza A virus poses a significant global health threat.
    • Developing effective antiviral therapies is crucial for managing influenza.
    • Selenocystamine inhibits influenza virus RNA-dependent RNA polymerase in vitro.

    Purpose of the Study:

    • To investigate the in vivo efficacy of selenocystamine and rifampicin against influenza A virus.
    • To determine the optimal concentrations for maximal inhibition of viral replication.

    Main Methods:

    • Influenza A/PR/8/34 (HON1) infection was established in embryonated eggs.
    • Eggs were treated with varying concentrations of selenocystamine and rifampicin post-infection.
    • Hemagglutinating and infective virus yields were measured to assess antiviral activity.

    Main Results:

    • Both selenocystamine and rifampicin completely inhibited hemagglutinating and infective virus yields.
    • Maximal inhibition was achieved with non-cytotoxic concentrations: 50 µg/egg for selenocystamine and 400 µg/egg for rifampicin.
    • Early administration of both drugs was critical for maximal efficacy.

    Conclusions:

    • Selenocystamine and rifampicin exhibit potent antiviral activity against influenza A virus in ovo.
    • These findings support the potential of selenocystamine and rifampicin as therapeutic agents for influenza infections.
    • Further research may explore combination therapies for enhanced influenza treatment.

    More Related Videos

    Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals09:31

    Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

    Published on: April 15, 2017

    Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

    Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

    Published on: April 4, 2019

    Related Concept Videos

    Influenza01:27

    Influenza

    Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
    Respiratory Syncytial Virus Disease01:29

    Respiratory Syncytial Virus Disease

    Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
    Inhibitors of Bacterial DNA Synthesis01:28

    Inhibitors of Bacterial DNA Synthesis

    Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
    Inhibitors of Viral Protein Synthesis01:30

    Inhibitors of Viral Protein Synthesis

    Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
    Inhibitors Of Virion Release01:25

    Inhibitors Of Virion Release

    Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
    Antiviral Nucleoside Inhibitors01:22

    Antiviral Nucleoside Inhibitors

    Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...